Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > STAB Statera Biopharma > Detailed Quotes

STAB Statera Biopharma

Watchlist
0.039
+0.003+8.33%
Trading Session  02/08 11:35 ET
High
0.040
Open
0.035
Turnover
8.41K
Low
0.035
Pre Close
0.036
Volume
223.30K
Market Cap
2.13M
P/E(TTM)
Loss
52wk High
1.060
Shares
54.66M
P/E(Static)
Loss
52wk Low
0.025
Float Cap
1.47M
Bid/Ask %
0.00%
Historical High
279.800
Shs Float
37.87M
Volume Ratio
0.61
Historical Low
0.025
Dividend TTM
--
Div Yield TTM
--
P/B
-0.21
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.59%
Amplitude
13.57%
Avg Price
0.037
Lot Size
1
Float Cap
1.47M
Bid/Ask %
0.00%
Historical High
279.800
Shs Float
37.87M
Volume Ratio
0.61
Historical Low
0.025
Dividend TTM
--
P/B
-0.21
Dividend LFY
--
Turnover Ratio
0.59%
Amplitude
13.57%
Avg Price
0.037
Lot Size
1
Price Forecast

News

Comment

Company Overview More
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia. The firm is developing therapies designed to directly elicit within patients a robust and durable response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205) in addition to expansion into fibromyalgia and multiple sclerosis. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.
CEO: Mr. Michael K. Handley
Market: Pink Market
Listing Date: 07/21/2006
Paper Trade More
Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist